Stana, M.; Grambozov, B.; Karner, J.; Gollner, I.; Gaisberger, C.; Ruznic, E.; Zellinger, B.; Moosbrugger, R.; Studnicka, M.; Fastner, G.;
et al. Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DLCO Correlate with Radiation Dosimetry and Pneumonitis Rate. Cancers 2023, 15, 1966.
https://doi.org/10.3390/cancers15071966
AMA Style
Stana M, Grambozov B, Karner J, Gollner I, Gaisberger C, Ruznic E, Zellinger B, Moosbrugger R, Studnicka M, Fastner G,
et al. Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DLCO Correlate with Radiation Dosimetry and Pneumonitis Rate. Cancers. 2023; 15(7):1966.
https://doi.org/10.3390/cancers15071966
Chicago/Turabian Style
Stana, Markus, Brane Grambozov, Josef Karner, Isabella Gollner, Christoph Gaisberger, Elvis Ruznic, Barbara Zellinger, Raphaela Moosbrugger, Michael Studnicka, Gerd Fastner,
and et al. 2023. "Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DLCO Correlate with Radiation Dosimetry and Pneumonitis Rate" Cancers 15, no. 7: 1966.
https://doi.org/10.3390/cancers15071966
APA Style
Stana, M., Grambozov, B., Karner, J., Gollner, I., Gaisberger, C., Ruznic, E., Zellinger, B., Moosbrugger, R., Studnicka, M., Fastner, G., Sedlmayer, F., & Zehentmayr, F.
(2023). Chemo-Radio-Immunotherapy for NSCLC III: ESR/ATS Thresholds for DLCO Correlate with Radiation Dosimetry and Pneumonitis Rate. Cancers, 15(7), 1966.
https://doi.org/10.3390/cancers15071966
